• Explore /
  • Poster
  • / Immune correlates of outcome in patients with leiomyosarcoma (LMS) treated with durvalumab plus olaparib or cediranib: Transcriptome analysis from the DAPPER study.

Immune correlates of outcome in patients with leiomyosarcoma (LMS) treated with durvalumab plus olaparib or cediranib: Transcriptome analysis from the DAPPER study.

Abstract Poster

Authors

Abdulazeez Salawu

Abdulazeez Salawu

Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada

Abdulazeez Salawu , Ming Han , Abha A. Gupta , Hal Berman , Ben X Wang , Thomas D Pfister , Alberto Hernando-Calvo , Esmail Mutahar Al-Ezzi , Olubukola Ayodele , Lee-Anne Stayner , Bernard Lam , Aaron Richard Hansen , Anna Spreafico , Philippe L. Bedard , Marcus O. Butler , Benjamin Haibe-Kains , Lisa Avery , Lillian L. Siu , Albiruni Ryan Abdul Razak

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Sarcoma

Track

Sarcoma

Sub Track

Soft Tissue Tumors

Clinical Trial Registration Number

NCT03851614

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 11567)

DOI

10.1200/JCO.2023.41.16_suppl.11567

Abstract #

11567

Poster Bd #

501

Abstract Disclosures

Similar Posters

First Author: Olubukola Ayodele

First Author: Alberto Hernando-Calvo

First Author: B.J. Rimel

First Author: Juan Francisco Rodriguez-Moreno